Nuclear and mitochondrial localization of the putative RNA helicase DHX32

Alli, Zaman; Ackerley, Cameron; Chen, Yong; Al‐Saud, Bandar; Abdelhaleem, Mohamed

doi:10.1016/j.yexmp.2006.07.005

Cited by 12 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The widespread expression of DHX32, and the high level of similarity between human and murine DHX32, suggests that DHX32 is a functionally important gene (25). DHX32 was observed to be dysregulated in lymphoid malignancies (6).…”

Section: Discussionmentioning

confidence: 99%

DHX32 expression is an indicator of poor breast cancer prognosis

et al. 2016

View full text Add to dashboard Cite

Abstract. Emerging evidence suggests that DEAH-box polypeptide 32 (DHX32) serves an important role in the progression and metastasis of cancer. However, the role of DHX32 in breast cancer remains to be completely elucidated. The aim of the present study was to evaluate the expression and clinical significance of DHX32 in breast cancer. The reverse transcription-quantitative polymerase chain reaction was performed to analyze DHX32 messenger (m)RNA expression, and western blotting and immunohistochemistry were performed to examine DHX32 protein expression in breast cancer and adjacent non-cancerous tissues. The association in breast cancer between DHX32 expression, clinicopathological features and prognosis was analyzed using 193 breast cancer tissue samples. The results of the present study demonstrated that breast cancer tissues exhibited increased DHX32 mRNA and protein expression compared with adjacent non-cancerous tissues (P<0.001). In addition, DHX32 expression was significantly associated with breast cancer clinical stage (P=0.006), histological grade (P=0.029), lymph node metastasis (P<0.001) and expression of the proliferation marker Ki-67 (P=0.004). Kaplan-Meier estimator analysis indicated that increased DHX32 expression is associated with poor prognosis in patients with breast cancer. Furthermore, the Cox proportional hazards model indicated that DHX32 expression is an independent prognostic factor for decreased overall survival and disease-free survival in patients with breast cancer. In conclusion, the results of the present study suggest that DHX32 overexpression is an unfavorable prognostic biomarker in breast cancer and a potential therapeutic target of future breast cancer treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

DHX32 expression is an indicator of poor breast cancer prognosis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…34 It has been reported that DHX32 is localized in the nucleus and mitochondria. 35 Chen et al 36 have reported that the constitutive expression of DHX32 leads to an altered subcellular localization ©2 0 1 1 L a n d e s B i o s c i e n c e .…”

Section: Discussionmentioning

confidence: 99%

Genome-wide comprehensive analysis of human helicases

Umate¹,

Tuteja²,

Tuteja³

2011

Communicative & Integrative Biology

107

View full text Add to dashboard Cite

“…It has been reported that DHX32 is located in the nucleus and mitochondrial in myeloid leukemia cells HL-60(Alli et al, 2006). In SW480 cells, β-catenin is constitutively accumulated in nucleus due to the loss of wild-type adenomatous polyposis coli (APC) (Korinek et al, 1997).…”

Section: Resultsmentioning

confidence: 99%

DHX32 Promotes Angiogenesis in Colorectal Cancer Through Augmenting β-catenin Signaling to Induce Expression of VEGFA

Lin

Fang

et al. 2017

EBioMedicine

View full text Add to dashboard Cite

We previously reported that overexpression of DHX32 contributes to the growth and metastasis of colorectal cancer (CRC). However, the underlying mechanism is not largely characterized. Herein, we reported that DHX32 in CRC cells upregulated expression of vascular endothelial growth factor A (VEGFA) at the transcription level through interacting with and stabilizing β-catenin. This promoted the recruitment of host endothelial cells to the tumor, and therefore, formation of microvessel in the tumor. Xenograft model revealed that depletion of DHX32 in CRC cells significantly reduced the microvessel density in the grafts and suppressed the growth of grafts. Furthermore, the expression level of DHX32 was positively associated with microvessel density in human CRC and poor outcome of CRC patients. Therefore, the report demonstrates that DHX32 is a pro-angiogenic factor, that inhibition of DHX32-β-catenin pathway can provide a strategy for CRC treatment, and that the expression level of DHX32 has the potential to serve as a biomarker for CRC diagnosis and prognosis.

show abstract

Nuclear and mitochondrial localization of the putative RNA helicase DHX32

Cited by 12 publications

References 15 publications

DHX32 expression is an indicator of poor breast cancer prognosis

DHX32 expression is an indicator of poor breast cancer prognosis

Genome-wide comprehensive analysis of human helicases

DHX32 Promotes Angiogenesis in Colorectal Cancer Through Augmenting β-catenin Signaling to Induce Expression of VEGFA

Contact Info

Product

Resources

About